For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of intangible assets | - | -649* | 0 | 58,710 |
| Revenue, net | 36,220 | 34,125 | 26,063 | 25,881 |
| Cost of product revenue | 1,897 | 1,520 | 1,238 | 12,379 |
| Intangible asset amortization | 316 | 966* | 315 | 1,616 |
| Gain on sale of future royalties, intellectual property, and other assets, net | 43,314 | - | - | - |
| Research and development | 4,392 | 2,620 | 3,432 | 3,433 |
| Selling, general and administrative | 20,783 | 20,354 | 16,935 | 20,782 |
| Total operating expenses | 25,175 | 22,974 | 20,367 | 24,215 |
| Income (gain) from operations | 52,146 | 9,315 | 4,143 | -71,039 |
| Loss on extinguishment of debt | -2,756 | - | - | - |
| Loss on sale of prv | - | -6,195* | 0 | 148,325 |
| Loss on derivative liability | -7,216 | - | - | - |
| Interest expense | 1,711 | 1,887* | 2,051 | 2,009 |
| Fair value adjustment related to warrant and cvr liability | -968 | -11,557* | 5,506 | 747 |
| Fair value adjustment related to investments | 216 | 34* | -124 | 2 |
| Interest and other income, net | 3,589 | -90* | 2,313 | 2,378 |
| Total other (expense) income | -7,342 | 3,351 | -5,120 | 147,945 |
| Income (loss) before income taxes | 44,804 | 12,666 | -977 | 76,906 |
| Income tax expense | 6,914 | 501 | -433 | 2,199 |
| Net income (loss) | 37,890 | 12,165 | -544 | 74,707 |
| Basic EPS | 0.62 | 0.216 | -0.01 | 1.24 |
| Diluted EPS | 0.6 | 0.204 | -0.01 | 1.21 |
| Basic Average Shares | 58,405,955 | 56,417,179 | 55,951,572 | 54,780,938 |
| Diluted Average Shares | 60,230,490 | 59,511,670 | 55,951,572 | 56,324,903 |
ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)